HIF-1α is an important pathway in LSCs, and the inhibition of the HIF-1α pathway can offer a treatment strategy to eliminate LSCs in CML 35. The gene discussed is HIF1A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.